Response Biomedical Corp. (Response) offers diagnostic technologies for the medical central-lab testing, point of care (POC) testing and on-site environmental testing markets. The Company operates through the research, development, commercialization and distribution of diagnostic technologies segment. The Company develops, manufactures and sells its RAMP system for the global medical point of care market, including cardiovascular testing, infectious disease testing market and the on-site environmental testing market, including biodefense and vector environmental testing. In the United States, its RAMP 200 Reader is limited to central-lab use with the cardiovascular tests. POC, on-site diagnostic tests (or assays) are non-laboratory-based tests performed using portable hand-held devices, compact desktop analyzers, single-use test cartridges and/or dipsticks. The Company's RAMP system is a platform technology that combines a fluorescence detection system with lateral flow immunoassays.